Friend or foe—The Pfizer‐BioNTech (BNT162b2) vaccination: A case report of reversible acute acalculous cholecystitis

We described a rare case of vaccine‐induced acalculous cholecystitis (ACC). A 52‐year‐old female developed ACC after 8 h of receiving a 3rd dose of the Pfizer‐BioNTech COVID‐19 vaccination. The symptoms subsided completely with conservative treatment for 12 days, and the ultrasound and laboratory fi...

Descripción completa

Detalles Bibliográficos
Autores principales: Wahlen, Bianca Maria, Peralta, Ruben, Al‐Thani, Hassan, El‐Menyar, Ayman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9280744/
https://www.ncbi.nlm.nih.gov/pubmed/35846906
http://dx.doi.org/10.1002/ccr3.6078
Descripción
Sumario:We described a rare case of vaccine‐induced acalculous cholecystitis (ACC). A 52‐year‐old female developed ACC after 8 h of receiving a 3rd dose of the Pfizer‐BioNTech COVID‐19 vaccination. The symptoms subsided completely with conservative treatment for 12 days, and the ultrasound and laboratory findings went back to normal.

Ejemplares similares